Kincell Bio, a cell therapy developer and manufacturer, has appointed Larry Pitcher as Chief Operating Officer (COO).

Pitcher brings extensive experience in the advanced therapies Contract Development and Manufacturing Organization (CDMO) space, having had P&L responsibility, deep operational experience including facility expansions and key leadership roles.

Experience

Most recently, Pitcher was VP and GM for Catalent’s Gene Therapy Sites in MD, their largest operation, which accounted for a significant share of the company’s annual revenue. While at Catalent, he scaled commercial manufacturing and operations, enhanced customer satisfaction, and drove double-digit growth in both revenue and profitability while expanding both clinical and commercial programs.

Previously, Pitcher was at Thermo Fisher where he established a growing presence in advanced therapies across a network of sites including a new mRNA business in Italy, a cell therapy business and clinical and commercial microbial and plasmid DNA services in the U.S.

Earlier in his career, Pitcher was GM and site head for Brammer Bio’s viral vector business, general manager at RTI Surgical’s German and French operations, and held various operational roles in Florida. He earned a B.S. in Industrial Engineering from Western Michigan University and an MBA from the University of Florida.

“I am delighted to join Kincell, which has a clear focus on solving technical challenges for their cell therapy clients, ensuring reliable supply, and ultimately supporting patients in need through operational excellence,” said Pitcher.

Related Insights

Other recent leadership appointments at Kincell include:

• Stewart McNaull, PhD, as Chief Commercial Officer (CCO)
• Mark R. Bamforth as Chief Executive Officer (CEO)